All In Biotech

Drug Trial Radar · NCT04710056

Compassionate Use or Expanded Access of Mibavademab

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 14, 2021

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes

Summary

As written by the sponsor on the registry.

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Conditions

  • Lipodystrophy
  • Generalized Lipodystrophy (GLD)
  • Monogenic Obesity (MOB)

Interventions

  • REGN4461Drug

    To be provided by Regeneron

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.